Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research
Open Access
- 17 October 2013
- journal article
- review article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 29 (3) , 148-167
Abstract
The American Society for Apheresis (ASFA) conducted a 1 day consensus conference on Thrombotic Thrombocytopenic Purpura (TTP) during its annual meeting in Atlanta, GA, on April 10, 2012. The authors of this article, a subcommittee of ASFA's Clinical Applications Committee, developed several questions with regard to definitions, classification, pathophysiology, diagnosis, management, and future research in TTP. These questions were provided to the seven invited speakers who are the experts in the field of TTP. Two moderators conducted the proceedings of the conference which was attended by more than 100 participants. After each presentation, there was an open discussion that included moderator‐selected written questions submitted by the audience. A medical writer‐generated transcript of the proceedings as well as each presentation was made available to the authors. Each summary was reviewed and approved by the respective speaker before submission of this article. The subcommittee also developed seven key questions for blinded, electronic polling conducted by the moderators to generate a consensus amongst the speakers. This article includes these presentation summaries as well as results of the electronic poll. J. Clin. Apheresis 29:148–167, 2014. © 2013 The Authors. Journal of Clinical Apheresis Published by Wiley Periodicals, Inc.Keywords
This publication has 65 references indexed in Scilit:
- The TITAN trial – Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpuraTransfusion and Apheresis Science, 2012
- Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE CohortPLOS Medicine, 2011
- N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and miceJournal of Clinical Investigation, 2011
- aHUS caused by complement dysregulation: new therapies on the horizonPediatric Nephrology, 2010
- Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779Journal of Thrombosis and Haemostasis, 2009
- Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpuraKidney International, 2009
- Frequency of Pro475Ser Polymorphism of ADAMTS13 Gene and Its Association with ADAMTS-13 Activity in the Korean PopulationYonsei Medical Journal, 2008
- Comparison and stability of ADAMTS13 activity in therapeutic plasma productsTransfusion, 2006
- ADAMTS13 and microvascular thrombosisExpert Review of Cardiovascular Therapy, 2006
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1982